Guzzo Nano Research

Guzzo Nano Research (GNR) aims to provide a new class of cancer therapeutic agents that bestows important benefits to both the patients and treating physicians. Working with multi-walled-carbon nanotubes (MWCNTs) GNR has developed a targeted nanotherapeutics technology for the photothermal treatment of prostate cancer (PCa). Although significant advances have been made in biological therapeutics, radiotherapy, and surgical techniques, most cancers remain incurable. The greatest threat to cancer therapeutics is genetic heterogeneity and the ability of the neoplasia to genetically evolve, and thus becoming resistant to treatment regimes. It is commonly accepted that the root of these tumor mutations is a selective pressure from these same biologics. Treatment relapse from PCa therapies results in more aggressive disease known as castrate resistant PCa (CRPC), where the therapeutic options are almost non-existent. Currently, GNR is in the pre-clinical stages assessing a nanoformulation for the treatment of PCa. GNR’s nanotherapeutic platform employs a physical-directed based treatment approach through tumor ablation, thereby circumventing the failures biologics. By harnessing the inherent physical properties of MWCNTs by differentiating itself with the following characteristics: 1. Conversion of light energy to generate extreme heat; 2. Easy functionalization of different tumor targeting molecules; 3. Excellent and safe systemic delivery properties without toxic or off-target effects. The placement of these particles at the tumor site and upon exposure to laser light would dissipate an extreme radius of heat thus, causing complete photothermal ablation of the cancerous lesion. The advantage of GNR’s nanotherapeutics technology is that provides an unchallenged therapeutic modality for treating PCa.